Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 10/20 | 0.68 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.65 |
| ▸ | REN | P00797 | 4/20 | 0.57 |
| ▸ | ACE | P12821 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30051626 | 0.87 | CTSD (0.57) | CTSDPSMB5 | |
| SCHEMBL6303137 | 0.86 | PSMB5 (0.67) | PSMB5RENACE | |
| SCHEMBL15692396 | 0.86 | PSMB5 (0.64) | CTSDPSMB5REN | |
| SCHEMBL11116006 | 0.85 | CTSS (0.60) | CTSD | |
| SCHEMBL11116015 | 0.85 | CTSS (0.60) | CTSD | |
| SCHEMBL17969275 | 0.85 | CTSD (0.85) | CTSD | |
| SCHEMBL17969276 | 0.85 | CTSD (0.85) | CTSD | |
| SCHEMBL17969277 | 0.85 | CTSD (0.85) | CTSD | |
| SCHEMBL10029540 | 0.85 | CTSD (0.68) | CTSDPSMB5REN | |
| SCHEMBL7373769 | 0.84 | ACE (0.74) | PSMB5ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9839665-B2 | Aminostatin derivatives for the treatment of arthrosis | MERCK PATENT GMBH (DE) | 2017-12-12 | — | — | US | disclosed |
| US-9839665-B2 | Aminostatin derivatives for the treatment of arthrosis | MERCK PATENT GMBH (DE) | 2017-12-12 | — | — | US | disclosed |
| EP-2673287-B1 | AMINO STATIN DERIVATIVES FOR THE TREATMENT OF ARTHROSIS | MERCK PATENT GMBH (DE) | 2017-08-30 | — | — | EP | disclosed |
| US-20160228493-A1 | AMINOSTATIN DERIVATIVES FOR THE TREATMENT OF ARTHROSIS | MERCK PATENT GMBH (DE) | 2016-08-11 | — | — | US | disclosed |
| US-20160228493-A1 | AMINOSTATIN DERIVATIVES FOR THE TREATMENT OF ARTHROSIS | MERCK PATENT GMBH (DE) | 2016-08-11 | — | — | US | disclosed |
| US-9345742-B2 | Aminostatin derivatives for the treatment of arthrosis | MERCK PATENT GMBH (DE) | 2016-05-24 | — | — | US | disclosed |
| US-9345742-B2 | Aminostatin derivatives for the treatment of arthrosis | MERCK PATENT GMBH (DE) | 2016-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160228493-A1 | AMINOSTATIN DERIVATIVES FOR THE TREATMENT OF ARTHROSIS | CTSD, CTSB, CTSZ | CTSD 1/4885PSMB5 2156/4885REN 879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.